韩国葡萄膜炎患者T-SPOT.TB检测的临床意义
该回顾性临床队列研究纳入2013至2022年在三级转诊中心诊断为葡萄膜炎且接受T-SPOT.TB检测和胸部影像的382例患者,其中125例(32.7%)T-SPOT.TB阳性。T-SPOT.TB阳性组平均年龄更高(55.9岁 vs 42.5岁,P < .001),既往结核病史比例更高(5.6% vs 0.8%,P = .007),但葡萄膜炎解剖分布及治疗模式无显著差异。作者认为在结核中等负担国家,T-SPOT.TB阳性可能反映背景潜伏感染而非活动性眼部受累。
要点
- 382例葡萄膜炎患者中32.7%为T-SPOT.TB阳性。
- 阳性组年龄更高且既往结核病史更多,但葡萄膜炎解剖分布和治疗模式无显著差异。
- 作者认为T-SPOT.TB阳性可能反映背景潜伏感染而非活动性眼部受累。
核心结论
- 在结核中等负担国家的真实世界队列中,T-SPOT.TB阳性与葡萄膜炎的临床特征或治疗负担无关。
- 作者认为葡萄膜炎患者T-SPOT.TB阳性可能反映背景潜伏感染而非活动性眼部受累。
研究设计与样本
- 回顾性临床队列研究,纳入2013至2022年在三级转诊中心诊断为葡萄膜炎且T-SPOT.TB检测结果可解释并接受胸部影像的382例患者。
- 比较T-SPOT.TB阳性组与阴性组的临床数据,包括葡萄膜炎解剖位置和治疗方案。
- 额外分析比较呼吸科转诊、抗结核治疗给药以及胸部影像和微生物学发现。
主要发现
- 382例患者中125例(32.7%)为T-SPOT.TB阳性。
- T-SPOT.TB阳性组平均年龄高于阴性组(55.9岁 vs 42.5岁,P < .001)。
- T-SPOT.TB阳性组既往结核病史比例高于阴性组(5.6% vs 0.8%,P = .007)。
- 两组葡萄膜炎解剖分布无显著差异(P = .073),治疗模式包括皮质类固醇单药治疗和使用免疫调节剂或生物制剂亦无显著差异(分别为P = .175和P = .238)。
- T-SPOT.TB阳性患者中54例(43.2%)转诊至呼吸科,14例接受潜伏性结核感染治疗,1例 later diagnosed with TB lymphadenitis 接受全疗程抗结核治疗,无患者证实活动性肺结核。
关键数值与推荐
- T-SPOT.TB阳性定义为检测结果可解释且阳性,原文未报告具体阈值。
- 葡萄膜炎解剖分布比较P = .073,皮质类固醇单药治疗比较P = .175,免疫调节剂或生物制剂使用比较P = .238。
- T-SPOT.TB阳性组125例中54例(43.2%)转诊呼吸科,14例接受潜伏性结核感染治疗,1例接受全疗程抗结核治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the clinical significance of T-SPOT.TB results in patients with uveitis in South Korea, an intermediate tuberculosis (TB) burden country, and to compare clinical characteristics and treatment patterns by T-SPOT.TB results. DESIGN: Retrospective clinical cohort study. METHODS: This study included 382 patients diagnosed with uveitis who underwent both T-SPOT.TB test with interpretable results and chest imaging at a tertiary referral center between 2013 and 2022. Clinical data, including the anatomical location of uveitis and treatment regimens, were compared between T-SPOT.TB-positive and negative groups. Additional analyses compared pulmonology referrals, antitubercular therapy administration, and chest imaging and microbiologic findings. RESULTS: Among 382 patients, 125 (32.7%) were T-SPOT.TB-positive. The T-SPOT.TB-positive group had a higher mean age (55.9 vs 42.5 years, P < .001) and a higher prevalence of prior TB history (5.6% vs 0.8%, P = .007). No significant differences were found in the anatomical distribution of uveitis (P = .073) or treatment patterns, including corticosteroid monotherapy and use of immunomodulatory agents or biologics (P = .175 and P = .238, respectively). Of the T-SPOT.TB-positive patients, 54 (43.2%), were referred to the pulmonology department, and 14 received treatment for latent TB infection, and 1 patient, later diagnosed with TB lymphadenitis, underwent full antitubercular therapy. No patients demonstrated active pulmonary TB. CONCLUSIONS: In this real-world cohort from a TB intermediate-burden country, T-SPOT.TB positivity was not associated with clinical features or treatment burden of uveitis. The findings suggest that T-SPOT.TB positivity in uveitis patients may reflect background latent infection rather than active ocular involvement.
引用
- Song JS, Song SH, Kim MS, et al. Clinical Significance of T-SPOT.TB Test in Patients With Uveitis in South Korea. Am J Ophthalmol. 2025. PMID: 41265719. doi:10.1016/j.ajo.2025.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。